For years we've stared at GWAS hits, knowing these variants matter but unable to say how. What I am excited about is that we can finally characterize them experimentally and at sufficient depth. We've done that for autoimmune diseases, and the biology surprised us: one might expect hundreds of idiosyncratic mechanisms, one per locus, but instead, the variants converged onto a set of shared regulatory programs. That convergence is what gives hope therapeutically. Mechanism-per-locus has long been the missing input for turning human genetics into drugs, and we can now supply it at scale." by Daniel Schraivogel, co-corresponding author.